Author Interviews, COVID -19 Coronavirus / 27.05.2020
JAK inhibitor Ruxolitinib Shows Promise in Mitigating Cytokine Storm of COVID-19
MedicalResearch.com Interview with:
Jianfeng Zhou MD, PhD
Department of Hematology, Tongji Hospital
Tongji Medical College
Huazhong University of Science and Technolog
Wuhan, Hubei, China
MedicalResearch.com: What is the background for this study?
Response: There is accumulating evidence on the key pathophysiological role of cytokines during the severe stage of COVID-19. In the context of lack of vaccine and specific antiviral agents, testing of immunomodulatory agents to reduce excessive or uncontrolled inflammation before it results in irreversible multi-organ dysfunction infection has received increasing research attention. Although several important papers have proposed JAK inhibitors as potential therapeutic targets, the role of JAK inhibitors on COVID-19 patients needs to be clarified quickly, especially in severe COVID-19 patients. (more…)